(Q51442140)

5 April 2018

title

Carcinoma of the larynx treated with hypofractionated radiation and hyperbaric oxygen: long-term tumor control and complications. (English)

1 reference

5 April 2018

0 references

Haffty BG

1

1 reference

5 April 2018

Hurley RA

series ordinal

2

1 reference

5 April 2018

Peters LG

series ordinal

3

1 reference

5 April 2018

language of work or name

English

0 references

publication date

1 August 1999

1 reference

5 April 2018

International Journal of Radiation Oncology Biology Physics

published in

1 reference

5 April 2018

volume

45

1 reference

5 April 2018

issue

1

1 reference

5 April 2018

page(s)

13-20

1 reference

5 April 2018

Hypoxia-Specific Cytotoxins in Cancer Therapy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

The leeds results for radiotherapy in HBO for carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Fast neutron irradiation of metastatic cervical adenopathy: The results of a randomized RTOG study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale Mitomycin Randomized Trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Radiotherapy and hyperbaric oxygen in head and neck cancer. Final report of first controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Late results of a trial of hyperbaric oxygen and radiotherapy in head and neck cancer: a rationale for hypoxic cell sensitizers?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Radiation therapy of head and neck tumors: A randomized study of treatment in air vs. treatment in hyperbaric oxygen

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Irradiation with misonidazole and hyperbaric oxygen: final report on a randomized trial in advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Enhancement of radiosensitivity of skin of patients by high pressure oxygen.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Randomized trial of conventional versus high fractional dose radiation therapy in the treatment of advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

The Results of Radiotherapy with High Pressure Oxygen in Carcinoma of the Pharynx, Larynx and Oral Cavity

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Pretherapeutic staging of laryngeal carcinoma. Clinical findings, computed tomography, and magnetic resonance imaging compared with histopathology.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Chemotherapy followed by accelerated fractionated radiation for larynx preservation in patients with advanced laryngeal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

The linear-quadratic formula and progress in fractionated radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Hypofractionation reduces the therapeutic ratio in early glottic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Management of advanced glottic cancer a 10 year review of the Toronto experience

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Stage T3 squamous cell carcinoma of the glottic larynx: A comparison of laryngectomy and irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Twice-daily fractionation schemes for advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Dose-response relationship for supraglottic laryngeal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Hemoglobin, radiation, morbidity and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Twice-a-day radiation therapy for supraglottic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

Larynx preservation with combined chemotherapy and radiation therapy in advanced but resectable head and neck cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2899%2900126-1

7 January 2021

10.1016/S0360-3016(99)00126-1

Identifiers

DOI

1 reference

5 April 2018

PubMed ID

10477001

1 reference

5 April 2018